Compare LYFT Inc (LYFT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Neurocrine Biosciences Inc — how do they compare? LYFT Inc trades at $16.21 (market cap $6.11B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.4× LYFT Inc's market cap, and LYFT Inc is more actively traded (13,504,560 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LYFT | NBIX | |
|---|---|---|
Market Cap | $6.11B | $14.36B |
Volume | 13,504,560 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $24.57 | $185.50 |
52-Week Low | $12.65 | $123.10 |
Typical Hold Time | 47 Days | 23 Days |
Enterprise Value | $5.57B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.22, up 3.97% with a bullish technical signal. The company shows strong profitability with 45.52% gross margins and 42.32% net income margin, though recent earnings missed expectations. Revenue growth continues from $4.1B in 2022 to $6.32B in 2025. Recent developments include European expansion and a $272.5M legal settlement. The stock trades below the $18.07 consensus price target with 22 buy, 35 hold, and 3 sell ratings.
Lyft presents a mixed outlook with strong cash flow generation and expanding operations balanced against recent earnings misses and competitive pressures. The bullish technical setup and below-consensus pricing suggest potential upside, but investors face risks from driver classification lawsuits, market volatility, and execution challenges in new markets.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
